Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Immune-Related Anhedonia in MDD
NCT07493317Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Mar 2026
- Primary completion
- Feb 2031
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in major depressive disorder (MDD), sponsored by Icahn School of Medicine at Mount Sinai. Started Mar 2026; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07493317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493317.